The GRHL2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the GRHL2 gene in the near-haploid HAP1 human cell line. This product consists of a heterogeneous pool of cells carrying diverse loss-of-function mutations introduced by CRISPR/Cas9, creating a robust model for studying GRHL2-dependent biology. The polyclonal format avoids the limitations of monoclonal lines, offering a genetically variable population suitable for pooled assays and dose-response studies. Supplied as a ready-to-use population, these cells serve as a versatile platform for investigating GRHL2-mediated transcriptional regulation and its associated pathways.
HAP1 is a near-haploid human cell line isolated from a chronic myeloid leukemia (CML) patient, expressing the BCR-ABL1 oncogenic fusion. Its haploid karyotype eliminates the issue of heterozygous mutations, allowing efficient CRISPR/Cas9-mediated gene disruption in a single step. This genetic simplicity makes HAP1 a favored host for functional genomics screens and knockout model generation. Despite its hematopoietic origin, the cell line retains key signaling modules and exhibits robust growth, ensuring reproducible results in downstream assays. The haploid background is particularly beneficial for polyclonal knockout populations, as it ensures strong phenotype penetrance even in a mixed cell pool.
GRHL2 encodes a transcription factor critical for epithelial cell adhesion and barrier integrity. It directly activates CDH1 (E-cadherin), CLDN4, OCLN, DSG3, and DSP, which form tight junctions and desmosomes. Upstream, TP63 induces GRHL2 expression, while ZEB1 and TGF-beta repress it during EMT. GRHL2 interacts with EP300, beta-catenin, and SMADs, integrating Wnt and TGF-beta signals. Its activity is counteracted by Hippo effectors YAP/TAZ. GRHL2 knockout disrupts these complexes, downregulates adhesion proteins, and compromises barrier function, promoting EMT and invasion.
In the HAP1 background, the GRHL2 polyclonal knockout enables dissection of GRHL2-dependent networks without confounding paralogs. Although HAP1 cells are non-epithelial, they harbor intact Wnt, TGF-beta, and Hippo pathways, and the haploid state enhances phenotype penetrance. This model is ideal for population-level assays, functional screens, and drug target studies where heterogeneous mutations reflect tumor variability. It allows investigation of EMT and adhesion dynamics in a genetically simple system, complementing epithelial cancer models.
The GRHL2 Knockout HAP1 Polyclonal Cells are suited for diverse research applications. Investigators can assay epithelial barrier function using TEER, localize junction proteins by immunofluorescence, and profile transcriptomes with RNA-seq. The model excels in EMT and metastasis studies, where GRHL2 loss enhances migration and invasion (wound healing/Transwell). It supports drug target validation for adhesion-dependent cancers (breast, lung, gastric) and functional analysis of deafness-related pathways. ChIP-qPCR enables mapping of GRHL2 genomic occupancy, while rescue experiments permit domain-specific characterization. For further details, contact Ascent Research.
